---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-25-000126"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2025-08-20T23:59:59+00:00"
generated_at: "2026-05-17T11:10:54.297087+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# GRI Bio files corporate presentation with no material new disclosures

## Summary
- Furnished a corporate presentation dated August 20, 2025 under Regulation FD.
- Presentation provides an overview of GRI Bio's approach to inflammatory diseases.
- No specific financial results, guidance, or material operational updates were disclosed.
- The filing is made under Item 7.01 and is not deemed filed for SEC purposes.
- Ticker: GRI; stock trades on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001824293-25-000126
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2025-08-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000126/0001824293-25-000126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000126/val-20250820.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-25-000126
- JSON: https://secwatch.observer/filing/0001824293-25-000126.json
- Plain text: https://secwatch.observer/filing/0001824293-25-000126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.